Xiaoxia Xu1, Hua Zhu1, Fei Liu1, Yan Zhang2, Jianhua Yang1, Lifang Zhang2, Qing Xie1, Lin Zhu2, Nan Li3, Hank F Kung4,5, Zhi Yang6. 1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China. 2. Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing, 100875, China. 3. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China. rainbow6238@sina.com. 4. Department of Radiology, University of Pennsylvania, Philadelphia, PA, 19104, USA. kunghf@outlook.com. 5. Beijing Institute for Brain Disorders, Capital Medical University, Beijing, 100069, China. kunghf@outlook.com. 6. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China. pekyz@163.com.
Abstract
PURPOSE: The purpose of this study was to compare dynamic 18F-FGln PET/CT images of healthy subjects and cancer patients and explore the best imaging phase for different cancers. METHODS: Thirteen healthy volunteers and 31 cancer patients separately underwent 18F-FGln and 18F-FDG PET/CT scans within 1 week. The distributions of 18F-FGln and 18F-FDG in the whole body and the tumor avidity were analyzed and compared. The tumor maximum standardized uptake values (SUVmax) and tumor-to-nontumor SUV ratio (SUR) of 18F-FGln/PET at different scan phases were compared. RESULTS: Compared to the healthy subjects, the cancer patients had lower 18F-FGln activity (SUVmean) in most normal organs, especially in the lung, muscle, spleen, and heart (p < 0.05). Additionally, the FGln-avid tumors did not necessarily manifest as FDG-avid and vice versa. Overall, among the 31 primary malignant lesions confirmed by biopsy or postoperative pathological analysis, 29 showed increased radioactive uptake on all 18F-FGln PET/CT imaging phases. The peak of SUVmax in breast and thyroid cancers was within 10 min, while in lung cancers, the plateau of SUVmax was within 30 min to 60 min. The SURs of lung cancer (p = 0.046) and thyroid cancer (p = 0.794) increased from the early-phase to the late-phase acquisition; however, a significant decrease was observed in the breast lesions (p = 0.022). CONCLUSIONS: 18F-FGln images may further supplement the diagnostic ability of 18F-FDG in cancer patients and detect metabolic changes in different tumors. Furthermore, the imaging time for 18F-FGln PET/CT needs to be optimized for different cancer types to improve the contrast resolution of tumors.
PURPOSE: The purpose of this study was to compare dynamic 18F-FGln PET/CT images of healthy subjects and cancerpatients and explore the best imaging phase for different cancers. METHODS: Thirteen healthy volunteers and 31 cancerpatients separately underwent 18F-FGln and 18F-FDG PET/CT scans within 1 week. The distributions of 18F-FGln and 18F-FDG in the whole body and the tumor avidity were analyzed and compared. The tumor maximum standardized uptake values (SUVmax) and tumor-to-nontumor SUV ratio (SUR) of 18F-FGln/PET at different scan phases were compared. RESULTS: Compared to the healthy subjects, the cancerpatients had lower 18F-FGln activity (SUVmean) in most normal organs, especially in the lung, muscle, spleen, and heart (p < 0.05). Additionally, the FGln-avid tumors did not necessarily manifest as FDG-avid and vice versa. Overall, among the 31 primary malignant lesions confirmed by biopsy or postoperative pathological analysis, 29 showed increased radioactive uptake on all 18F-FGln PET/CT imaging phases. The peak of SUVmax in breast and thyroid cancers was within 10 min, while in lung cancers, the plateau of SUVmax was within 30 min to 60 min. The SURs of lung cancer (p = 0.046) and thyroid cancer (p = 0.794) increased from the early-phase to the late-phase acquisition; however, a significant decrease was observed in the breast lesions (p = 0.022). CONCLUSIONS: 18F-FGln images may further supplement the diagnostic ability of 18F-FDG in cancerpatients and detect metabolic changes in different tumors. Furthermore, the imaging time for 18F-FGln PET/CT needs to be optimized for different cancer types to improve the contrast resolution of tumors.
Authors: Varsha Viswanath; Rong Zhou; Hsiaoju Lee; Shihong Li; Abigail Cragin; Robert K Doot; David A Mankoff; Austin R Pantel Journal: J Nucl Med Date: 2020-12-04 Impact factor: 10.057
Authors: Allison S Cohen; Joe Grudzinski; Gary T Smith; Todd E Peterson; Jennifer G Whisenant; Tiffany L Hickman; Kristen K Ciombor; Dana Cardin; Cathy Eng; Laura W Goff; Satya Das; Robert J Coffey; Jordan D Berlin; H Charles Manning Journal: J Nucl Med Date: 2021-04-30 Impact factor: 11.082
Authors: Evelien A J van Genugten; Jetty A M Weijers; Sandra Heskamp; Manfred Kneilling; Michel M van den Heuvel; Berber Piet; Johan Bussink; Lizza E L Hendriks; Erik H J G Aarntzen Journal: Front Oncol Date: 2022-01-07 Impact factor: 6.244